CARDINAL HEALTH INC

Cardinal Health’s atumelnant shows early promise for CAH and Cushing’s, offering an oral ACTH‑antagonist that reduces cortisol and androgen levels safely.

Cardinal Health’s Rule 144 filing shows insider sales, market effects, and future risks—offering investors insight into liquidity, regulatory shifts, and potential upside.

Cardinal Health’s 10‑year stock gains exceed 160% (and nearly 200% with splits/dividends), driven by strong valuations, cash flow, and a growing digital supply‑chain moat—yet regulatory shifts, tariffs and AI logistics could reshape future returns.

Cardinal Health’s Q3 2026 earnings beat expectations, driven by a growing pharmaceutical division and strategic acquisitions, boosting revenue and guidance while analysts weigh integration risks and rising specialty drug margins.

Cardinal Health’s strategic blend of tech‑driven logistics, value‑based reimbursement alignment, and cost‑efficient operations fuels 15% CAGR growth and high margins in the US healthcare supply chain.

Cardinal Health’s shift to value‑based logistics and high‑margin dental specialties drives stronger returns and growth potential—discover why it’s a top healthcare supply‑chain pick.

Cardinal Health tops Q2 earnings expectations, boosting revenue and EPS while raising FY‑2024 guidance and launching a share‑buyback that lifts shareholder value.

Cardinal Health sees institutional buying as a sign of confidence while its strong supply‑chain moat and resilient valuation support steady investor interest.

Cardinal Health’s Q2 2026 earnings reveal how the pharmacy‑distributor blends high‑margin manufacturing, digital analytics and value‑based care to outpace rivals while navigating FDA and PBM scrutiny.

Cardinal Health Inc. announces its Q2 2026 earnings on Feb 5, highlighting AI inventory, telepharmacy, and robust supply‑chain resilience for investors.